gdc
Breast CancerWeb Exclusives

The Benefit of CDK4/6 Inhibitors Applies Equally to Older Women with Breast Cancer

Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who are treated with a CDK4/6 inhibitor may derive benefits similar to those seen in their younger counterparts.

Web Exclusives – February 26, 2018

To date, 3 CDK4/6 inhibitors have been approved by the FDA for the treatment of patients with breast cancer: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). These agents work by blocking the function of proteins CDK4 and CDK6, both which drive cell multiplication, thereby fueling tumor growth.

Treatment with CDK4/6 inhibitors appears to have the same efficacy in older patients with breast cancer, compared with younger ones, according to new findings presented at the 2017 San Antonio Breast Cancer Symposium.

“As we approve new drugs to treat cancer, it is important to try to improve our understanding of the efficacy and safety of these drugs in our older patients,” said the study’s lead investigator, Harpreet Singh, MD, Medical Officer, Scientific Liaison, Cancer in Older Adults, Office of Hematology and Oncology Products, FDA. “Older patients traditionally have been underrepresented in oncology clinical trials, so pooling outcomes of older patients across clinical trials in the same drug class allows us to gain insight into how these patients may benefit.”

To determine the efficacy and safety of CDK4/6 inhibitors in an older population, Dr Singh and colleagues pooled and analyzed data from randomized controlled trials that evaluated the 3 FDA-approved CDK4/6 inhibitors in combination with an aromatase inhibitor, as the first-line treatment for postmenopausal women with hormone receptor–positive metastatic breast cancer. The cohort included 1334 patients (intention-to-treat population, 1992), of whom 42% were aged ≥65 years, and 24% were ≥70 years.

The primary end point of the study was progression-free survival (PFS) in patients aged ≥70 years, and in control groups.

In patients aged ≥70 years who were treated with a CDK4/6 inhibitor in combination with an aromatase inhibitor, the estimated PFS was not reached, compared with an estimated PFS of 16.8 months for those treated only with an aromatase inhibitor.

In patients aged <70 years who were treated with a CDK4/6 inhibitor, the estimated PFS was 23.8 months, compared with an estimated 13.8 months for those treated only with an aromatase inhibitor.

The researchers also evaluated safety in 1106 patients who received ≥1 doses of a CDK4/6 inhibitor.

Older patients were more likely than the younger patients to discontinue treatment because of side effects. Twenty percent of the patients aged <70 years discontinued treatment, compared with 17% of patients aged ≥65 years and 8% of those aged <65 years. The most common events that led to discontinuation of treatment across all age-groups were infection, fatigue, blood count abnormalities (neutropenia), liver enzyme abnormalities, and diarrhea.

“Our findings suggest that there is no treatment difference across age subgroups in terms of efficacy of CDK4/6 inhibitors,” Dr Singh said. “This is an important piece of information as health care providers and patients weigh their treatment options as new therapies are approved.”

A co-investigator on the study, Lynn Howie, MD, a medical officer in the FDA Center for Drug Evaluation and Research, Office of Hematology and Oncology Products, added that the potential benefit of a CDK4/6 inhibitor for older patients with breast cancer should be weighed against the increased risk for toxicity. In addition to the higher rates of discontinuation of treatment, older patients often required more dose modifications to help them manage side effects.

Source:

Singh H, Howie LJ, Bloomquist E, et al. A U.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS5-06.

Recommended For You
Breast CancerPatient Advocacy
Finding Our Voices, Telling Our Stories: Metastatic Breast Cancer Advocacy
By Meg Barbor, MPH
Musa Mayer, breast cancer survivor and advocate, was recently recognized for her 25 years of advocacy on behalf of patients with advanced breast cancer. Read Musa’s inspiring story.
Breast CancerNewsworthy
Living Beyond Breast Cancer to Host 12th Annual National Metastatic Breast Cancer Conference in Philadelphia, April 20-22
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer.
Breast CancerNewsworthyWeb Exclusives
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
SlideshowsWeb Exclusives
Testicular Cancer Awareness Month
April is Testicular Cancer Awareness Month! Take a cruise through this slideshow full of facts about testicular cancer, such as the common risk factors and symptoms to look out for. Conquer cancer with knowledge.
Last modified: March 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Need multiple copies? Click here